EORTC - European Organisation for Research and Treatment of Cancer’s Post

📚 🩺 Results of the EORTC LungTech trial assessing the safety and efficacy of stereotactic body radiotherapy (SBRT) in patients with centrally located early-stage NSCLC have been recently published. The trial shows that SBRT with 8 × 7.5Gy in inoperable patients is a viable treatment option. However, careful dose management and post-SBRT interventions are essential to mitigate the risk of potentially fatal toxicities. Learn more: https://lnkd.in/eqSGqeFh #CancerResearch #ClinicalTrials #Oncology #LungCancer #NSCLC #SBRT #ThoracicOncology

Alberto Bossi, MD, highlights the importance of recognizing different side effect profiles when discussing treatment options with prostate cancer patients. Despite similar efficacy rates across treatments like radical prostatectomy, external beam radiotherapy, and brachytherapy, each approach presents unique side effects. Patients should understand that their decision shouldn't solely focus on treatment efficacy but also on managing potential side effects. Dr. Bossi stresses the need for thorough patient discussions to ensure informed decision-making. #Radonc #Brachytherapy #Prostatecancer #Oncology https://lnkd.in/eHYFyHVr

Alberto Bossi, MD, highlights the importance of recognizing different side effect profiles when discussing treatment options with prostate cancer patients. Despite similar efficacy rates across treatments like radical prostatectomy, external beam radiotherapy, and brachytherapy, each approach presents unique side effects. Patients should understand that their decision shouldn't solely focus on treatment efficacy but also on managing potential side effects. Dr. Bossi stresses the need for thorough patient discussions to ensure informed decision-making. #Radonc #Brachytherapy #Prostatecancer #Oncology https://lnkd.in/dQ_cUTT9

Alberto Bossi, MD, highlights the importance of recognizing different side effect profiles when discussing treatment options with prostate cancer patients. Despite similar efficacy rates across treatments like radical prostatectomy, external beam radiotherapy, and brachytherapy, each approach presents unique side effects. Patients should understand that their decision shouldn't solely focus on treatment efficacy but also on managing potential side effects. Dr. Bossi stresses the need for thorough patient discussions to ensure informed decision-making. #Radonc #Brachytherapy #Prostatecancer #Oncology https://lnkd.in/dGuCxYTw

Alberto Bossi, MD, highlights the importance of recognizing different side effect profiles when discussing treatment options with prostate cancer patients. Despite similar efficacy rates across treatments like radical prostatectomy, external beam radiotherapy, and brachytherapy, each approach presents unique side effects. Patients should understand that their decision shouldn't solely focus on treatment efficacy but also on managing potential side effects. Dr. Bossi stresses the need for thorough patient discussions to ensure informed decision-making. #Radonc #Brachytherapy #Prostatecancer #Oncology https://lnkd.in/gD5CtN3b

Alberto Bossi, MD, highlights the importance of recognizing different side effect profiles when discussing treatment options with prostate cancer patients. Despite similar efficacy rates across treatments like radical prostatectomy, external beam radiotherapy, and brachytherapy, each approach presents unique side effects. Patients should understand that their decision shouldn't solely focus on treatment efficacy but also on managing potential side effects. Dr. Bossi stresses the need for thorough patient discussions to ensure informed decision-making. #Radonc #Brachytherapy #Prostatecancer #Oncology https://lnkd.in/eSG9vzSG

David Büchser, MD, highlights the precision of prostate brachytherapy: • Allows extreme dose escalation within the prostate. • Maximizes tumor control while preserving healthy tissue. • Reduces rates of acute and late toxicities. • Benefits low and favorable intermediate-risk patients as monotherapy. • Proven effectiveness in combination with external beam radiation for high-risk cases. Find out more https://lnkd.in/eSG9vzSG #Brachytherapy #Radonc #Brachytherapy #Prostatecancer #Oncology

Alberto Bossi, MD, highlights the importance of recognizing different side effect profiles when discussing treatment options with prostate cancer patients. Despite similar efficacy rates across treatments like radical prostatectomy, external beam radiotherapy, and brachytherapy, each approach presents unique side effects. Patients should understand that their decision shouldn't solely focus on treatment efficacy but also on managing potential side effects. Dr. Bossi stresses the need for thorough patient discussions to ensure informed decision-making. #Radonc #Brachytherapy #Prostatecancer #Oncology https://lnkd.in/gNrNcjhW

Insightful registry-based research by Oskar Franklin, MD, PhD, and team (DOI: 10.1245/s10434-024-15157-4), as seen in Ann Surg Oncol, scrutinizes adjuvant chemotherapy alongside radiotherapy in resected pancreatic cancer patients who've undergone neoadjuvant chemotherapy. The survival benefits are marked, with the greatest advantage seen in those with grade 3 tumors and lymphovascular invasion 🛡️. Such data are crucial for tailoring post-surgical treatment protocols. #CancerTreatment #Oncology #ClinicalOutcomes In the quest for longevity, it seems combining forces yields the best arsenal. 🤝

🚨Highlights from ESMO 2024! Dr Michael Saerens, medical oncologist at University Hospital Ghent, shares key findings from recent clinical trials in head & neck cancer, including: - Weekly cisplatin shows non-inferiority with fewer side effects in SCCHN. - GORTEC REACH trial shows no added benefit of avelumab, cetuximab, and radiotherapy. - Setanaxib combined with pembrolizumab offers improved survival in recurrent/metastatic SCCHN. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #Oncology #HeadAndNeckCancer #ClinicalTrials #Immunotherapy